Three-week Topical Treatment with Placenta-Derived Mesenchymal Stem Cells Hydrogel in a Patient with Diabetic Foot Ulcer: A Case Report

Xiangxia Zeng,Yunliang Tang,Kaixiang Hu,Wang Jiao,Liu Ying,Lingyan Zhu,Jianying Liu,Jixiong Xu

DOI: https://doi.org/10.1097/md.0000000000009212

IF: 1.6

2017-01-01

Medicine

Abstract:Rationale:Diabetic foot ulcer (DFU) is a chronic complication of diabetes characterized by continuity, repeatability, and nonhealing. In recent years, mesenchymal stem cells hydrogel complex has been a new emerging technique in the treatment of DFU. The placenta-derived mesenchymal stem cells (PDMSCs) hydrogel is multipotent, and can secrete growth factors, cytokines, and immunomodulatory substances which could accelerate wound healing.Patient concerns:In this case report, we present a 57-year-old female with type 2 diabetes mellitus and a 20-day DFU.A wound bed located at the dorsalis pedis of the right foot, and conventional therapies had no effect on the foot.Diagnoses:The patient was confirmed a diagnosis of type 2 DM with diabetic foot (Wagner classification III).Interventions:To assess the efficacy and safety of PDMSCs hydrogel in wound repair and to improve the rate of wound healing, we administered PDMSCs hydrogel (cell number: 1x10(6)/cells/cm(2)) topically into the wound with the patient's permission.Outcomes:The patient's foot ulcer was almost healed, and foot function in walking was well preserved. No complications were observed. No recurrence occurred in the subsequent 6 months.Lessons:To the best of our knowledge, this is the first patient globally to receive PDMSCs hydrogel to treat DFU. The present case study suggests that PDMSCs hydrogel may provide a new approach to DFU treatment. Clinical Trial Registration-URL: http://www.chictr.org.cn/searchproj.aspx:chiCRT-ONC-16008732.